Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.41 |
| ▸ | NPY4R | P50391 | 9/20 | 0.40 |
| ▸ | NPY1R | P25929 | 6/20 | 0.40 |
| ▸ | NPY2R | P49146 | 5/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | TFPI | P10646 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31031613 | 0.96 | NOD1 (0.43) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30974097 | 0.93 | GLO1 (0.41) | NPY4RNPY1RNPY2RNPY5RKEAP1 | |
| SCHEMBL13496859 | 0.93 | NPY4R (0.40) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL7394659 | 0.93 | NPY4R (0.40) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29404748 | 0.91 | NOD1 (0.47) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31091376 | 0.91 | NPY4R (0.45) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29391114 | 0.91 | NOD1 (0.44) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31000882 | 0.91 | PTGS1 (0.45) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30567417 | 0.89 | NOD1 (0.42) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29642947 | 0.89 | TFPI (0.44) | NPY4RNPY1RNPY2RNPY5RKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718687-B2 | Biomoletron for regulation stem cell differentiation | SOGANGN UNIVERSITY RESEARCH FOUNDATION (KR) | 2023-08-08 | — | — | US | claimed |
| EP-4631545-A1 | METHOD FOR TREATING ULCERATIVE COLITIS OR PRIMARY SCLEROSING CHOLANGITIS | Kyoto University (JP) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024122553-A1 | METHOD FOR TREATING ULCERATIVE COLITIS OR PRIMARY SCLEROSING CHOLANGITIS | 国立大学法人京都大学 | 2024-06-13 | — | — | WO | disclosed |
| WO-2023191209-A1 | MICELLE INCLUDING HYDROPHILIC PEPTIDE AND USE THEREOF | 주식회사 퓨전바이오텍 | 2023-10-05 | — | — | WO | disclosed |
| US-7446120-B2 | Peptidomimetic modulators of cell adhesion | ADHEREX TECHNOLOGIES, INC. (CA) | 2008-11-04 | — | — | US | disclosed |
| US-20080081831-A1 | PEPTIDOMIMETIC MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2008-04-03 | — | — | US | disclosed |
| US-7268115-B2 | Cyclic peptides; three-dimensional structures; screening; anticancer agents; angiogenesis inhibitors; drug delivery | ADHEREX TECHNOLOGIES, INC. (CA) | 2007-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081831-A1 | PEPTIDOMIMETIC MODULATORS OF CELL ADHESION | CDH1, EPCAM, VCAM1 | NOD1 1944/4885NPY4R 2823/4885NPY1R 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.